Preclinical study of cardiovascular regenerative medicine using asialoerythropoietin

细胞疗法的应用一直存在技术和伦理问题。替代药物，如细胞因子，而不是培养细胞，可能有助于解决这些问题。亚洲资源促红细胞生成素（AEPO）是促红细胞生成素的天然衍生物，在心血管和中枢神经系统的血管生成和组织保护中起重要作用。我们开始了AEPO的体内外作用的临床前研究。AEPO在体内具有较强的心血管保护和血管生成活性。EPO衍生物在体外血管生成活性表达的内在依赖于IL-6的方式。AEPO在体外和体内均表现出组织亲和性。我们已经与一家合作公司就AEPO的临床应用进行了谈判。

There have been technical and ethical problems for the application of cell therapy. Alternative medical such as cytokines other than cultured cells may help resolvingtheseproblems. Asialresourcesoerythropoietin(AEPO), a natural derivative of EPO, plays important role in angiogenesis and tissue protection of cardiovascular and central nervous systems. We started the preclinical studies on the in vitro and in vivo effects of AEPO. AEPO exerted strong cardiovasculoprotective and angiogenic activity in vivo. EPO derivatives expressed in vitro angiogenic activity in an intrinsic IL-6 dependent manner. AEPO showed tissue affinity in vitro and in vivo. We have entered into negotiations with a partner company for clinical applications of AEPO.